Andrew Hindman, Theravance CFO
July 14, 2022 11:05 AM EDTUpdated July 15, 10:26 AM
Deals

Ther­a­vance, In­no­vi­va sell roy­al­ty rights on GSK's Trel­e­gy to Roy­al­ty Phar­ma for $1.3B up­front

Paul Schloesser

Associate Editor

Roy­al­ty Phar­ma is shelling out the big bucks to get its hands on roy­al­ties for a GSK drug.

Ther­a­vance Bio­phar­ma put out word Wednes­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times